ZMAT3
Overview
ZMAT3 (zinc finger matrin-type 3) is a p53-induced RNA-binding protein involved in regulating mRNA stability and splicing. It has been reported as the most upregulated gene in uterine leiomyomas regardless of driver type. In endometrial polyp genomics, ZMAT3 emerges as the top differentially upregulated gene in HMGA1/2-aberrant polyps, suggesting it is a downstream effector of HMGA-driven transcriptional reprogramming.
Alterations observed in the corpus
- ZMAT3 is the top differentially upregulated gene in HMGA1/HMGA2-aberrant endometrial polyps by 3′RNA-seq (q = 6.98 × 10⁻¹³, log2FC = 1.65 vs normal endometrium); no direct DNA-level mutations in ZMAT3 were reported PMID:28445112.
- ZMAT3 upregulation parallels its previously described role as the most upregulated gene in uterine leiomyomas (ULM) regardless of driver, flagged by the same research group, suggesting shared HMGA-driven biology across benign uterine neoplasms PMID:28445112.
Cancer types (linked)
- Endometrial polyps (related to UCEC): top upregulated gene (q = 6.98 × 10⁻¹³) in HMGA-aberrant polyps; not directly mutated PMID:28445112.
Co-occurrence and mutual exclusivity
- ZMAT3 transcriptional upregulation co-occurs with HMGA1 and HMGA2 rearrangements as a downstream consequence PMID:28445112.
Therapeutic relevance
- Authors suggest cross-disease shared biology: any HMGA-targeted therapy (e.g., HMGA2 gene silencing explored in ovarian carcinoma) could in principle also suppress ZMAT3 upregulation across HMGA-driven uterine lesions PMID:28445112.
Open questions
- Whether ZMAT3 upregulation has a functional role in polyp/leiomyoma biology or is simply a bystander biomarker of HMGA activity has not been determined PMID:28445112.
Sources
This page was processed by crosslinker on 2026-05-14.